Sampre Nutrition

Why is Sampre Nutritions Ltd falling/rising?

As of 19-Jun, Sampre Nutritions Ltd's stock price is at 8.11, reflecting a significant decline of -67.40% year-to-date and a continuous downward trend over the past week. The stock is underperforming against the benchmark Sensex and shows bearish indicators with decreasing investor participation.

As of 19-Jun, Sampre Nutritions Ltd's stock price is falling, currently at 8.11, which reflects a change of -0.42 or -4.92%. The stock has been on a downward trend, having lost value for the last seven consecutive days, resulting in a total decline of -29.9% during this period. Over the past week, the stock has underperformed significantly, with a decrease of -22.39%, while the benchmark Sensex has gained +1.69%. <BR><BR>In addition to the recent price drop, Sampre Nutritions Ltd has shown poor performance over longer periods, with a year-to-date decline of -67.40%, compared to a -9.88% drop in the Sensex. The stock is also trading below its moving averages across multiple time frames, indicating a bearish trend. Furthermore, investor participation appears to be declining, as evidenced by a -12.88% drop in delivery volume compared to the five-day average. This combination of factors contributes to the ongoing decline in the stock's price.

Which are the latest news on Sampre Nutrition?

What does Sampre Nutrition do?

Sampre Nutritions Ltd manufactures sugar candies and operates in the FMCG sector, primarily producing candy products for Cadbury India Ltd. As of March 2026, it reported net sales of 15 Cr and a net profit of 1 Cr, with a market cap of INR 108 Cr.

Overview: <BR>Sampre Nutritions Ltd is engaged in the manufacturing of sugar candies and operates within the FMCG industry, categorized as a micro-cap company.<BR><BR>History: <BR>Incorporated in 1991, Sampre Nutritions Ltd was promoted by The Gurbani Group. The company has been manufacturing candy products for Cadbury India Ltd since August 1996 and entered into an agreement to manufacture "DAIRY MILK ECLAIRS" in 2000. The latest reported quarter for net sales and profit is March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 15 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 108 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 31.00 <BR>Industry P/E: 45 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.17 <BR>Return on Equity: 3.33% <BR>Price to Book: 0.98 <BR><BR>Contact Details: <BR>Address: P No 133 Indl Estate, Medchal Telangana: 501401 <BR>Tel: 91-08418-222427/28 <BR>Email: gurbani@gurbanigroup.in <BR>Website: http://www.sampreltd.com

How big is Sampre Nutrition?

As of 10th June, Sampre Nutritions Ltd has a market capitalization of 108.00 Cr, with recent net sales of 43.36 Cr and a net profit of 3.58 Cr. Shareholder's funds are 90.88 Cr and total assets are valued at 115.43 Cr as of March 2025.

As of 10th June, Sampre Nutritions Ltd has a market capitalization of 108.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sampre Nutritions Ltd reported Net Sales of 43.36 Cr and a Net Profit of 3.58 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 90.88 Cr and Total Assets valued at 115.43 Cr.

Who are in the management team of Sampre Nutrition?

The management team of Sampre Nutrition includes B K Gurbani (Managing Director), Vishal Ratan Gurbani (Vice President & Whole-Time Director), and several Independent Directors: Banala Jayaprakash Reddy, Umra Singh Sirohi, and Vimal Suresh, along with Deepak Bissa (Company Secretary & Compliance Officer).

The management team of Sampre Nutrition includes the following individuals:<BR><BR>1. **B K Gurbani** - Managing Director<BR>2. **Banala Jayaprakash Reddy** - Independent Director<BR>3. **Umra Singh Sirohi** - Independent Director<BR>4. **Vishal Ratan Gurbani** - Vice President & Whole-Time Director<BR>5. **Vimal Suresh** - Independent Director<BR>6. **Deepak Bissa** - Company Secretary & Compliance Officer<BR><BR>If you need more details about their roles or contributions, feel free to ask!

Who are the peers of the Sampre Nutrition?

Sampre Nutrition's peers include Tirupati Starch, Norben Tea, Valencia Nutrit., and others. It has below-average management risk and growth, with a 1-year return of 97.50%, lower than Norben Tea's 124.56% but higher than B & A's -28.65%.

Peers: The peers of Sampre Nutrition are Tirupati Starch, Norben Tea, Valencia Nutrit., Tanvi Foods, Mayank Cattle Fo, Vistar Amar, B & A, Thrive Future Ha, and James Warren Tea.<BR><BR>Quality Snapshot: Excellent management risk is observed at Vistar Amar, while Average management risk is found at Tirupati Starch, Norben Tea, Mayank Cattle Fo, B & A, and James Warren Tea. Below Average management risk is present at Sampre Nutrition, Valencia Nutrit., Tanvi Foods, Thrive Future Ha, and Grob Tea Co. Growth is classified as Excellent at Vistar Amar, Good at Valencia Nutrit., and Below Average at Sampre Nutrition, Tirupati Starch, Norben Tea, Tanvi Foods, Thrive Future Ha, and Grob Tea Co. Capital Structure ratings show Excellent at Vistar Amar, Average at B & A, and Below Average at Sampre Nutrition, Tirupati Starch, Norben Tea, Valencia Nutrit., Tanvi Foods, Mayank Cattle Fo, Thrive Future Ha, James Warren Tea, and Grob Tea Co.<BR><BR>Return Snapshot: Norben Tea has the highest 1-year return at 124.56%, while B & A has the lowest at -28.65%. Sampre Nutrition's 1-year return of 97.50% is significantly higher than B & A's but lower than Norben Tea's. Additionally, the six-month returns for Tirupati Starch, Valencia Nutrit., Sampre Nutrition, Tanvi Foods, Thrive Future Ha, James Warren Tea, and Grob Tea Co. are all negative.

Should I buy, sell or hold Sampre Nutritions Ltd?

When is the next results date for Sampre Nutritions Ltd?

The next results date for Sampre Nutritions Ltd is 13 February 2026.

The next results date for Sampre Nutritions Ltd is scheduled for 13 February 2026.

Are Sampre Nutrition latest results good or bad?

Sampre Nutrition's latest Q2 FY26 results show significant improvements in net profit and revenue growth, but challenges remain with weak capital efficiency and declining long-term profitability. Overall, while there are positive signs, investors should be cautious due to ongoing structural weaknesses.

Sampre Nutrition's latest results for Q2 FY26 show a mixed performance. On the positive side, the company reported a net profit of ₹0.90 crores, which is a significant improvement of 650% year-on-year and a 26.76% increase from the previous quarter. Revenue also grew by 37.55% year-on-year to ₹10.00 crores, although it experienced an 8% decline compared to the previous quarter.<BR><BR>The operating margin improved to 19.50%, marking the highest level in seven quarters, indicating better cost management and operational efficiency. However, the company faces challenges with weak capital efficiency, as reflected in its average return on equity (ROE) of just 1.71%, which is among the lowest in its peer group.<BR><BR>While the quarterly results indicate a recovery from previous losses, the overall financial health remains concerning due to a flat annual performance in FY25, with a net loss of ₹7.00 crores. The company's long-term profitability has also been in decline, as evidenced by a negative five-year EBIT compound annual growth rate (CAGR) of -238.74%.<BR><BR>In summary, while there are positive signs in the latest quarterly results, the underlying issues of weak capital efficiency and long-term profitability challenges suggest that the results are not entirely good. Investors should approach with caution, considering both the recent improvements and the ongoing structural weaknesses.

How has been the historical performance of Sampre Nutrition?

Sampre Nutrition experienced a significant decline in financial health from March 2024 to March 2025, with net sales slightly decreasing and total expenditure rising sharply, resulting in a negative operating profit and a loss after tax of -7.67 Cr. Despite an increase in total assets, the company's financial outlook is concerning due to negative profit margins and escalating costs.

Answer:<BR>The historical performance of Sampre Nutrition shows a significant decline in financial health from March 2024 to March 2025.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Sampre Nutrition reported net sales of 25.12 Cr, a slight decrease from 25.15 Cr in the previous year. Total operating income mirrored this trend, remaining nearly unchanged at 25.12 Cr compared to 25.15 Cr in March 2024. However, total expenditure saw a substantial increase to 28.99 Cr from 21.02 Cr, primarily driven by a rise in employee costs from 7.75 Cr to 10.81 Cr and other expenses escalating from 3.74 Cr to 9.82 Cr. This led to an operating profit (PBDIT) of -3.50 Cr, a stark contrast to the positive 4.25 Cr reported in the prior year. Consequently, profit before tax plummeted to -7.52 Cr from 0.49 Cr, resulting in a profit after tax of -7.67 Cr compared to a modest profit of 0.23 Cr in March 2024. The earnings per share also reflected this downturn, falling to -3.65 from 0.32. On the balance sheet, total liabilities surged to 115.43 Cr from 44.75 Cr, while total assets increased to the same figure, indicating a significant rise in the company's financial obligations. The book value per share improved to 42.44 from 26.75, but the overall financial outlook for Sampre Nutrition appears concerning, with negative profit margins and increasing costs overshadowing any positive asset growth.

Who are the top shareholders of the Sampre Nutrition?

The top shareholder of Sampre Nutrition is Wave Capital Ltd, holding 12.52% of the shares. Individual shareholders own 31.28%, with Brahma Gurbani as the largest promoter at 4.94%, and there are no pledged promoter holdings or investments from mutual funds or foreign institutional investors.

The top shareholders of Sampre Nutrition include Wave Capital Ltd, which holds the largest public share at 12.52%. Among individual shareholders, they collectively own 31.28% of the company. The promoter with the highest holding is Brahma Gurbani, who owns 4.94%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

Is Sampre Nutrition overvalued or undervalued?

As of June 5, 2025, Sampre Nutrition is considered overvalued with a risky valuation grade, reflected by a PE ratio of -7.39, an EV to EBITDA ratio of -19.19, and a troubling ROE of -35.54%, significantly underperforming its peers and the market with a year-to-date return of -60.75%.

As of 5 June 2025, Sampre Nutrition's valuation grade has moved from expensive to risky, indicating a significant shift in its perceived value. The company is currently assessed as overvalued. Key ratios highlight its precarious position: the PE ratio stands at -7.39, the EV to EBITDA ratio is at -19.19, and the ROE is a concerning -35.54%. <BR><BR>In comparison to its peers, Sampre Nutrition's metrics are starkly unfavorable; for instance, Hindustan Unilever has a PE ratio of 53.88, while Nestlé India boasts a PE of 75.2. This stark contrast underscores the challenges Sampre faces in the FMCG sector. Additionally, the company's stock performance has been disappointing, with a year-to-date return of -60.75%, significantly underperforming the Sensex's 5.62% return.

What is the technical trend for Sampre Nutrition?

As of June 4, 2025, Sampre Nutrition's technical trend has shifted to a moderate bearish stance, supported by bearish signals from Bollinger Bands, moving averages, and monthly MACD, despite some mildly bullish indicators on the weekly timeframe.

As of 4 June 2025, the technical trend for Sampre Nutrition has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the weekly MACD showing mildly bullish but the monthly MACD is bearish, indicating a divergence in trends. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the bearish outlook. Daily moving averages are also bearish. The KST shows a mildly bullish signal on the weekly but is bearish on the monthly, while the Dow Theory indicates a mildly bearish stance on the weekly with no trend on the monthly. Overall, the combination of these indicators suggests a bearish sentiment in the current market environment.

Has Sampre Nutrition declared dividend?

No Dividend History Available